Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]
Awaiting development
Reference number: GID-TA11840
Expected publication date: TBC
We anticipate that the evaluation will begin during late January 2028 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately late March 2028.